Veradermics, Incorporated (MANE) - Net Assets
Based on the latest financial reports, Veradermics, Incorporated (MANE) has net assets worth $391.87 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($398.58 Million) and total liabilities ($6.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Veradermics, Incorporated tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $391.87 Million |
| % of Total Assets | 98.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 297.67 |
Veradermics, Incorporated - Net Assets Trend (2023–2025)
This chart illustrates how Veradermics, Incorporated's net assets have evolved over time, based on quarterly financial data. See MANE days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Veradermics, Incorporated (2023–2025)
The table below shows the annual net assets of Veradermics, Incorporated from 2023 to 2025. For live valuation and market cap data, see Veradermics, Incorporated (MANE) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-121.01 Million | -321.37% |
| 2024-12-31 | $54.66 Million | +273.96% |
| 2023-12-31 | $14.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Veradermics, Incorporated's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10067800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $60.00K | % |
| Other Components | $2.35 Million | % |
| Total Equity | $-121.01 Million | 100.00% |
Veradermics, Incorporated Competitors by Market Cap
The table below lists competitors of Veradermics, Incorporated ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Allete Inc
NYSE:ALE
|
$3.94 Billion |
|
Trex Company Inc
NYSE:TREX
|
$3.95 Billion |
|
Shanghai Wanye Enterprises Co Ltd
SHG:600641
|
$3.95 Billion |
|
GEPIC Energy Development Co Ltd
SHE:000791
|
$3.95 Billion |
|
Tutor Perini Corporation
NYSE:TPC
|
$3.94 Billion |
|
FOSITEK CORP
TW:6805
|
$3.94 Billion |
|
Wuhan Raycus Fiber Laser Technologies Co Ltd Class A
SHE:300747
|
$3.94 Billion |
|
K.P.R. Mill Limited
NSE:KPRMILL
|
$3.94 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Veradermics, Incorporated's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 54,665,000 to -121,014,000, a change of -175,679,000 (-321.4%).
- Net loss of 69,995,000 reduced equity.
- New share issuances of 159,433,000 increased equity.
- Other comprehensive income increased equity by 60,000.
- Other factors decreased equity by 265,177,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-70.00 Million | -57.84% |
| Share Issuances | $159.43 Million | +131.75% |
| Other Comprehensive Income | $60.00K | +0.05% |
| Other Changes | $-265.18 Million | -219.13% |
| Total Change | $- | -321.37% |
Book Value vs Market Value Analysis
This analysis compares Veradermics, Incorporated's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $0.07 | $96.07 | x |
| 2024-12-31 | $0.27 | $96.07 | x |
| 2025-12-31 | $-3.45 | $96.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Veradermics, Incorporated utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-53.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -112.81% | 0.00% | 0.00x | 1.26x | $-17.95 Million |
| 2024 | -48.46% | 0.00% | 0.00x | 1.09x | $-31.95 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-57.89 Million |
Industry Comparison
This section compares Veradermics, Incorporated's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $135,339,148
- Average return on equity (ROE) among peers: -67.83%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Veradermics, Incorporated (MANE) | $391.87 Million | -112.81% | 0.02x | $3.94 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $84.92 Million |
| Abcellera Biologics Inc (ABCL) | $966.90 Million | -15.14% | 0.40x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $314.56 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $45.35 Million | -59.09% | 0.17x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-5.75 Million | 0.00% | 0.00x | $30.94 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.69 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.61 Billion |
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in t… Read more